Conexeu Sciences Advances Wound Care Device Toward 2027 FDA Submission
Event summary
- Conexeu Sciences completed manufacturing scale-up for Ten Minute Tissue™, meeting predefined specifications.
- The company is on track for a planned FDA 510(k) submission in Q1 2027.
- Preclinical testing, biocompatibility studies, and commercial manufacturing readiness are underway.
- Ten Minute Tissue™ is designed to address irregularly shaped wounds with liquid-to-gel transition properties.
The big picture
Conexeu Sciences is advancing its lead wound care device, Ten Minute Tissue™, toward a planned FDA submission in early 2027. The company's progress in manufacturing scale-up and regulatory testing reflects its strategy to leverage the 510(k) pathway for faster market entry. The broader regenerative medicine sector is increasingly focused on scalable, biomimetic solutions, and Conexeu's platform could capture significant share if cleared.
What we're watching
- Regulatory Pathway
- Whether Conexeu can secure FDA clearance through the 510(k) pathway without delays or additional data requests.
- Commercial Readiness
- The pace at which Conexeu can establish scalable manufacturing to meet potential market demand post-clearance.
- Market Differentiation
- How Ten Minute Tissue™'s liquid-to-gel transition will position it against existing wound care solutions.